ARRY-382-Keytruda Combo Shows Positive Results in Ovarian, Other Solid Cancers
News
The combination of Array BioPharma‘s immunotherapy ARRY-382 and Keytruda (pembrolizumab) has a manageable safety profile and has shown preliminary signs of effectiveness in pancreatic and ovarian cancer patients, a new Phase 1b ... Read more